RepliCel Life Sciences Valuation
Is RP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RP's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RP's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RP?
Key metric: As RP is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is RP's PE Ratio? | |
|---|---|
| PE Ratio | 0.1x |
| Earnings | CA$1.37m |
| Market Cap | CA$191.21k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.3x |
| Enterprise Value/EBITDA | -2.7x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does RP's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
SE Sweet Earth Holdings | 2.7x | n/a | CA$496.1k |
CPTR Captor Capital | 0.1x | n/a | CA$2.8m |
DCNN Digicann Ventures | 0.04x | n/a | CA$441.1k |
SILO Silo Wellness | 2.2x | n/a | CA$1.5m |
RP RepliCel Life Sciences | 0.1x | n/a | CA$136.5k |
Price-To-Earnings vs Peers: RP is good value based on its Price-To-Earnings Ratio (0.1x) compared to the peer average (1.3x).
Price to Earnings Ratio vs Industry
How does RP's PE Ratio compare vs other companies in the North American Life Sciences Industry?
Price-To-Earnings vs Industry: RP is good value based on its Price-To-Earnings Ratio (0.1x) compared to the Global Life Sciences industry average (35.8x).
Price to Earnings Ratio vs Fair Ratio
What is RP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 0.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RP's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Cresco Labs
CA$744.9m
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.
CL
CA$1.72
7D
3.0%
1Y
-25.2%
Decibel Cannabis
CA$27.7m
An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.
DB
CA$0.065
7D
0%
1Y
-50.0%
Bausch Health Companies
US$2.9b
Operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
BHC
US$11.39
7D
-0.8%
1Y
18.8%